Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724643 | SCV000230003 | likely pathogenic | not provided | 2015-03-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000021959 | SCV000817625 | pathogenic | Biotinidase deficiency | 2023-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 245 of the BTD protein (p.Cys245Tyr). This variant is present in population databases (rs397507175, gnomAD 0.002%). This missense change has been observed in individual(s) with biotinidase deficiency (PMID: 15776412, 28971021). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 38281). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BTD protein function. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000021959 | SCV002017996 | pathogenic | Biotinidase deficiency | 2019-08-05 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000021959 | SCV002506313 | likely pathogenic | Biotinidase deficiency | 2022-02-22 | criteria provided, single submitter | clinical testing | The BTD c.734G>A; p.Cys245Tyr variant (rs397507175) is reported in the literature in multiple individuals affected with profound biotinidase deficiency usually (Jay 2015, Porta 2017, Wolf 2005). This variant is reported in ClinVar (Variation ID: 38281) and is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The cysteine at codon 245 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.924). Based on available information, this variant is considered to be likely pathogenic. References: Jay AM et al. Outcomes of individuals with profound and partial biotinidase deficiency ascertained by newborn screening in Michigan over 25 years. Genet Med. 2015 Mar;17(3):205-9. PMID: 25144890. Porta F et al. Neonatal screening for biotinidase deficiency: A 30-year single center experience. Mol Genet Metab Rep. 2017 Sep 20;13:80-82. PMID: 28971021. Wolf B et al. Biotinidase deficiency: novel mutations and their biochemical and clinical correlates. Hum Mutat. 2005 Apr;25(4):413. PMID: 15776412. |
Baylor Genetics | RCV000021959 | SCV004211407 | pathogenic | Biotinidase deficiency | 2023-10-12 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000021959 | SCV000797130 | likely pathogenic | Biotinidase deficiency | 2019-03-02 | no assertion criteria provided | clinical testing |